Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the second quarter — with an asterisk shaped like the novel coronavirus.

You may have heard something about a global, all-hands push to develop new medicines to treat Covid-19. This work will extend way beyond the second quarter, but the first (and therefore most highly anticipated) effort is expected to read out Phase 3 results in the next few weeks. All eyes will be on Gilead Sciences, which hopes to show that intravenously infused doses of the antiviral drug remdesivir are safe for patients and effective against Covid-19.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy